Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Parkinson's disease
Biotech
Takeda drops AZ-partnered neurological program after ph. 2 fail
Takeda has given up on an AstraZeneca-partnered neurological disorder program after the therapy flunked a phase 2 study.
James Waldron
Oct 30, 2025 9:25am
2 European biotechs link to tackle neurodegenerative diseases
Oct 20, 2025 8:20am
Irish biotech launches with $21M to shuttle RNAi meds to brain
Oct 1, 2025 10:34am
Thermo Fisher debuts protein panel for neurodegeneration R&D
Sep 16, 2025 12:00pm
AC Immune cuts workforce by 30%, trims pipeline to preserve cash
Sep 4, 2025 10:27am
Novartis aims at alpha-synuclein again with $2.2B Arrowhead deal
Sep 2, 2025 9:55am
